Acción A061250 HWAIL PHARMACEUTICAL CO.,LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Hwail Pharmaceutical Co.,Ltd.

Acciones

A061250

KR7061250007

Precio de cierre Korea S.E.
Otros sitios de cotización
 00:00:00 10/06/2024 		Varia. Cinco días. Varia. 1 de enero.
1.512 KRW -0,66 % Gráfico intradía de Hwail Pharmaceutical Co.,Ltd. +0,13 % -31,43 %
2023 Hwail Pharmaceutical Co.,Ltd. (KOSDAQ:A061250) anuncia una recompra de acciones por valor de 5.000 millones de KRW. CI
2023 Hwail Pharmaceutical Co.,Ltd. autoriza un Plan de Recompra. CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on August 21, 2023, has expired with 2,340,000 shares, representing 3.52% for KRW 4,980.33 million.
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
Hwail Pharmaceutical Co.,Ltd.(KOSDAQ:A061250) dropped from S&P Global BMI Index
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 1,519,180 shares, representing 2.23% for KRW 4,999.11 million.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 5.0000013 billion in funding from Osung Advanced Materials Co., Ltd.
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción A061250
  4. Noticias Hwail Pharmaceutical Co.,Ltd.
  5. Otros idiomas